Sustainability and the contribution to and impact of global warming have been key discussion points within the pharmaceutical industry over the last few years, with increasing attention on how pharmaceutical companies contribute towards a more sustainable healthcare sector.
Inhalers for asthma and COPD are also part of the sustainability conversation, in part due to the propellant gases found in pressurized metered dose inhalers (pMDIs).
In this webinar, we will explore how the Pharmaceutical industry’s use of propellants has evolved in the drive for greater sustainability including a reduction in the carbon footprint of inhalers, providing some context on the impact pMDIs have on the environment today while at the same time suggesting some areas for improvement. We will review the key considerations and challenges involved in developing more sustainable inhalers, involving many different stakeholders, including the developers and manufacturers of inhaler devices, the propellants, as well as patient compliance and recycling initiatives. We will also discuss the challenges ahead in R&D, regulatory and manufacturing of these low carbon inhalers and provide a road map as to how Aptar Pharma and our collaborative partners can help de-risk and accelerate our customers’ programs in the development, scale-up and commercialisation of inhalers with lower Global Warming Potential ( GWP).
We will also discuss how greater patient adherence could be an effective route to improved sustainability.
Director of Business Development, Pulmonary Category, Aptar Pharma